UCB SA (OTCMKTS:UCBJY) Short Interest Up 31.3% in July

UCB SA (OTCMKTS:UCBJY) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 4,200 shares, a growth of 31.3% from the June 30th total of 3,200 shares. Based on an average daily volume of 16,200 shares, the days-to-cover ratio is currently 0.3 days.

UCB Price Performance

OTCMKTS UCBJY traded up $1.48 on Friday, hitting $82.57. 6,144 shares of the stock traded hands, compared to its average volume of 18,483. The business’s fifty day moving average is $73.94 and its two-hundred day moving average is $62.96. UCB has a 12 month low of $34.85 and a 12 month high of $82.71.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.